The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has reported its position regarding Avadel Pharmaceuticals plc under the Irish Takeover Panel rules. On December 16, 2025, Vanguard disclosed holding approximately 5.87% of Avadel’s ordinary shares, totaling 5,713,129 shares. This exceeds the 1% threshold necessitating disclosure under rule 8.3.

In recent transactions, Vanguard purchased 55,944 Avadel ordinary shares at $21.37 each and sold 266 shares at the same price. There were no cash-settled or stock-settled derivative positions to disclose.

Vanguard confirmed no indemnity or informal options arrangements exist with any parties involved. There are also no agreements affecting voting rights or future acquisitions. No supplementary documentation has been attached to this disclosure.